Phastar Scoops Prestigious 2024 Scrip Award
LONDON and DURHAM, N.C., Dec. 9, 2024 /PRNewswire/ -- Phastar, a global specialist biometrics contract research organization (CRO), has won the...
Clinical Trial
Carta Healthcare to Power Oncology Research and Clinical Trials with Acquisition of Realyze Intelligence, a UPMC Enterprises Company
Clinician-trained AI analyzes electronic records to match ideal patients with studies in seconds rather than hours, optimizing research and reducing...
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of...
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide KELOWNA, BC / ACCESSWIRE / December 9,...
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025
PluriCDMO™, the Company’s contract development and manufacturing organization, recognized as a leading manufacturing collaborator offering scalability and mass scale production...
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release...
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW...
Safety Shot Announces Online Retail Expansion with one of the US Largest Big Box Store’s E-Commerce Platform
JUPITER, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or “the Company”) today announced...
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in...
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025SAN DIEGO, Dec. 09, 2024 (GLOBE...
Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a...
Evaxion announces 2025 milestones reflecting continued strong strategy execution
With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones...
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of...
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant...
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San...
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder ValueCORAL GABLES, Fla., Dec. 09, 2024 (GLOBE...
EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024
PRESS RELEASE EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024 Paris, France,...
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD, Mass., Dec. 09,...